Company: TVRD
Filing Date: 2025-02-14
Form Type: 424B3
Source: 0001104659-25-014310
Chunk: 322

Company: Tvardi Therapeutics, Inc.
Filing Date: 2025-02-14
Form: 424B3
Chunk 322
---
 Merger. Indemnification and Insurance For a discussion of the indemnification and insurance provisions related to the Cara directors and officers under the Merger Agreement, please see the section titled, see the section titled “ The Merger Agreement — Other Agreements — Director Indemnification and Insurance. ” Ownership Interests of Tvardi Directors and Executive Officers As of January 15, 2025, Tvardi’s executive officers and directors and such directors affiliated funds beneficially owned, in the aggregate, approximately 26.38% of the shares of Tvardi common stock. See the section titled “ Principal Stockholders of Tvardi ” beginning on page 405of this proxy statement/prospectus for additional information. Certain Tvardi officers and directors, and their affiliates, have also entered into the Support Agreements in connection with the Merger. For a more detailed discussion of the Support Agreements, please see the section titled “ Agreements Related to the Merger ” beginning on page 214of this proxy statement/prospectus. Executive Officers of the Combined Company Following the Merger Immediately following the Merger, the executive management team of the combined company is expected to comprise of the following individuals with such additional officers as may be added by Tvardi or the combined company:

| Name                        | ​ | ​ | Position with theCombined Company                     | ​ | ​ | Current Position at Tvardi                            | ​ |
| Imran Alibhai, Ph.D.        | ​ | ​ | Chief Executive Officer and Director                  | ​ | ​ | Chief Executive Officer and Director                  | ​ |
| Dan Conn, J.D., M.B.A.      | ​ | ​ | Chief Financial Officer                               | ​ | ​ | Chief Financial Officer                               | ​ |
| John Kauh, M.D.             | ​ | ​ | Chief Medical Officer                                 | ​ | ​ | Chief Medical Officer                                 | ​ |
| Jeffrey Larson, Ph.D., DABT | ​ | ​ | Senior Vice President, Research & Development         | ​ | ​ | Senior Vice President, Research & Development         | ​ |
| Yixin “Joseph” Chen, Ph.D.  | ​ | ​ | Vice President, Chemistry, Manufacturing and Controls | ​ | ​ | Vice President, Chemistry, Manufacturing and Controls | ​ |

Directors of the Combined Company Following the Merger At the Effective Time, the combined company is expected to initially have a seven-member board of directors, comprising (a) Sujal Shah, Michael W